MedWatch

Bavarian Nordic has initiated phase III of Covid-19 booster

The first of 4,000 patients has received a booster shot produced by the Danish drugmaker as part of a new, global phase III study of the company’s candidate.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

The first person has received Bavarian Nordic’s Covid-19 booster candidate, ABNCoV2, in a global phase III trial, the Danish vaccine maker announces in a press release.

”Trial will assess non-inferiority of ABNCoV2 compared to Comirnaty in terms of neutralizing antibodies against the SARS-CoV-2 (Wuhan wild type) as the primary endpoint, and other variants of concern as secondary endpoints,” reads the statement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs